

Market Announcement

14 December 2018

Paradigm Biopharmaceuticals Limited (ASX: PAR) – Trading Halt

Description

The securities of Paradigm Biopharmaceuticals Limited ('PAR') will be placed in trading halt at the request of PAR, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Tuesday, 18 December 2018 or when the announcement is released to the market.

Issued by

Kate Kidson

Principal Adviser, Listings Compliance (Melbourne)



14 December 2018

By email: kate.kidson@asx.com.au

Kate Kidson
Adviser, Listings Compliance (Melbourne)
ASX Limited

Dear Kate

Request for a trading halt

Paradigm Biopharmaceuticals Limited ACN 169 346 963 (ASX: PAR) (the **Company**), requests an immediate trading halt be granted for all of its securities.

In accordance with Listing Rule 17.1, the Company advises:

- the trading halt is requested pending an announcement regarding the Company's Phase 2b placebo controlled OA/BMEL clinical trial results;
- the trading halt is requested to apply until the earlier of an announcement by the Company on the results of the clinical trial, or the commencement of normal trading on Tuesday 18th December 2018; and
- the Company is not aware of any reason why a trading halt should not be granted.

Please contact us should you have any questions.

Yours faithfully

Kevin Hollingsworth
Company Secretary
For and on behalf of the Board of Paradigm Biopharmaceuticals Limited

Paradigm BioPharmaceuticals Ltd
C/- Hollingsworth & Co Pty Ltd, Level 2, 517 Flinders Lane, Melbourne, VIC, 3000, AUSTRALIA
ABN: 94 169 346 963
Web: <http://paradigmbiopharma.com/>